Ionis Pharmaceuticals (IONS) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Ionis Pharmaceuticals Revenue Highlights


Latest Revenue (Y)

$787.65M

Latest Revenue (Q)

$225.00M

Main Segment (Y)

Research and Development Revenue

Ionis Pharmaceuticals Revenue by Period


Ionis Pharmaceuticals Revenue by Year

DateRevenueChange
2023-12-31$787.65M34.18%
2022-12-31$587.00M-27.53%
2021-12-31$810.00M11.11%
2020-12-31$729.00M-35.08%
2019-12-31$1.12B87.27%
2018-12-31$599.67M18.12%
2017-12-31$507.67M46.46%
2016-12-31$346.62M22.18%
2015-12-31$283.70M32.47%
2014-12-31$214.16M45.41%
2013-12-31$147.28M44.33%
2012-12-31$102.05M2.99%
2011-12-31$99.09M-8.65%
2010-12-31$108.47M-10.80%
2009-12-31$121.60M13.44%
2008-12-31$107.19M53.96%
2007-12-31$69.62M183.80%
2006-12-31$24.53M-38.87%
2005-12-31$40.13M-5.84%
2004-12-31$42.62M-14.73%
2003-12-31$49.99M-37.65%
2002-12-31$80.18M50.51%
2001-12-31$53.27M43.00%
2000-12-31$37.26M9.90%
1999-12-31$33.90M-13.52%
1998-12-31$39.20M20.62%
1997-12-31$32.50M43.81%
1996-12-31$22.60M73.85%
1995-12-31$13.00M28.71%
1994-12-31$10.10M-16.53%
1993-12-31$12.10M-

Ionis Pharmaceuticals generated $787.65M in revenue during NA 2023, up 34.18% compared to the previous quarter, and up 131.35% compared to the same period a year ago.

Ionis Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-06-30$225.00M88.29%
2024-03-31$119.50M-63.18%
2023-12-31$324.50M125.35%
2023-09-30$144.00M-23.40%
2023-06-30$188.00M43.51%
2023-03-31$131.00M-13.82%
2022-12-31$152.00M-4.86%
2022-09-30$159.77M19.42%
2022-06-30$133.79M-5.73%
2022-03-31$141.92M-67.75%
2021-12-31$440.00M230.60%
2021-09-30$133.09M5.84%
2021-06-30$125.75M12.67%
2021-03-31$111.61M-61.51%
2020-12-31$290.00M81.16%
2020-09-30$160.08M9.99%
2020-06-30$145.54M9.13%
2020-03-31$133.37M-73.00%
2019-12-31$494.00M194.24%
2019-09-30$167.89M2.37%
2019-06-30$164.00M-44.82%
2019-03-31$297.21M54.71%
2018-12-31$192.11M32.13%
2018-09-30$145.40M23.48%
2018-06-30$117.75M-18.47%
2018-03-31$144.42M-16.18%
2017-12-31$172.30M42.50%
2017-09-30$120.91M16.09%
2017-06-30$104.15M-5.58%
2017-03-31$110.30M-31.21%
2016-12-31$160.35M44.55%
2016-09-30$110.93M188.35%
2016-06-30$38.47M4.33%
2016-03-31$36.87M-28.50%
2015-12-31$51.57M4.99%
2015-09-30$49.12M-59.21%
2015-06-30$120.43M92.43%
2015-03-31$62.58M-26.25%
2014-12-31$84.86M92.59%
2014-09-30$44.06M-22.80%
2014-06-30$57.08M102.68%
2014-03-31$28.16M-33.35%
2013-12-31$42.25M79.14%
2013-09-30$23.59M-38.08%
2013-06-30$38.09M-12.15%
2013-03-31$43.36M118.19%
2012-12-31$19.87M71.30%
2012-09-30$11.60M-75.49%
2012-06-30$47.34M103.74%
2012-03-31$23.23M-28.29%
2011-12-31$32.40M56.44%
2011-09-30$20.71M-16.56%
2011-06-30$24.82M17.38%
2011-03-31$21.15M-19.96%
2010-12-31$26.42M-7.70%
2010-09-30$28.62M21.79%
2010-06-30$23.50M-21.46%
2010-03-31$29.93M-7.24%
2009-12-31$32.26M20.51%
2009-09-30$26.77M-13.62%
2009-06-30$30.99M-1.85%
2009-03-31$31.58M52.83%
2008-12-31$20.66M-35.87%
2008-09-30$32.22M-2.26%
2008-06-30$32.96M54.36%
2008-03-31$21.35M-13.64%
2007-12-31$24.73M-

Ionis Pharmaceuticals generated $225.00M in revenue during Q2 2024, up 88.29% compared to the previous quarter, and up 171.76% compared to the same period a year ago.

Ionis Pharmaceuticals Revenue Breakdown


Ionis Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
SPINRAZA Royalties$240.38M$292.99M---
Licensing and Other Royalties$33.30M$30.99M$19.12M$8.12M$17.20M
Other Commercial$68.21M----
Product$34.91M$30.05M$70.00M$42.25M-
Research and Development Revenue$479.06M$284.01M---
Commercial$308.59M$303.36M$342.39M$364.70M$352.45M
Collaborative Agreement Revenue$352.66M$207.22M---
Spinraza Royalties-$242.31M$267.78M$286.58M-
Eplontersen Joint Development Revenue-$76.79M---
Research and Development Revenue Under Collaborative Agreements--$468.06M$364.56M$770.15M
TEGSEDI and WAYLIVRA--$55.50M--

Ionis Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Research and Development Revenue (31.58%), Collaborative Agreement Revenue (23.25%), Commercial (20.34%), SPINRAZA Royalties (15.84%), Other Commercial (4.50%), Product (2.30%), and Licensing and Other Royalties (2.19%).

Quarterly Revenue by Product

Product/ServiceJun 24Dec 23Sep 23Jun 23
Collaborative Agreement Revenue$141.52M$179.14M$44.17M$91.01M
Commercial$72.04M$78.84M$84.08M$77.90M
Licensing and Other Royalties$3.32M$13.71M$8.54M-
Other Commercial$11.51M$34.50M$16.83M$16.89M
Product$8.19M$20.15M$8.29M-
Research and Development Revenue$153.21M$245.66M$60.13M$110.51M
SPINRAZA Royalties$56.74M$112.11M$67.25M$61.01M
Eplontersen Joint Development Revenue--$15.96M$19.50M

Ionis Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Research and Development Revenue (34.31%), Collaborative Agreement Revenue (31.69%), Commercial (16.13%), SPINRAZA Royalties (12.71%), Other Commercial (2.58%), Product (1.83%), and Licensing and Other Royalties (0.74%).

Ionis Pharmaceuticals Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
INCYIncyte$3.70B$962.99M
BMRNBioMarin Pharmaceutical$2.42B$733.87B
EXELExelixis$1.83B$478.06M
ALNYAlnylam Pharmaceuticals$1.83B$420.15M
SRPTSarepta Therapeutics$1.24B$413.46M
PTCTPTC Therapeutics$937.82M$186.70M
HALOHalozyme Therapeutics$829.25M$290.08M
IONSIonis Pharmaceuticals$787.65M$225.00M
APLSApellis Pharmaceuticals$366.28M$179.14M
ARWRArrowhead Pharmaceuticals$240.74M-
KRYSKrystal Biotech$50.70M$70.28M
IOVAIovance Biotherapeutics$1.19M$31.11M
VKTXViking Therapeutics--
MDGLMadrigal Pharmaceuticals-$62.17M
TERNTerns Pharmaceuticals--
AKROAkero Therapeutics--

IONS Revenue FAQ


Ionis Pharmaceuticals's yearly revenue for 2023 was $787.65M, representing an increase of 34.18% compared to 2022. The company's yearly revenue for 2022 was $587M, representing a decrease of -27.53% compared to 2021. IONS's yearly revenue for 2021 was $810M, representing an increase of 11.11% compared to 2020.

Ionis Pharmaceuticals's quarterly revenue for Q2 2024 was $225M, a 88.29% increase from the previous quarter (Q1 2024), and a 19.68% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $119.5M, a -63.18% decrease from the previous quarter (Q4 2023), and a -8.78% decrease year-over-year (Q1 2023). IONS's quarterly revenue for Q4 2023 was $324.5M, a 125.35% increase from the previous quarter (Q3 2023), and a 113.49% increase year-over-year (Q4 2022).

Ionis Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -2.76%, and for the last 5 years (2019-2023) was -29.86%.

Ionis Pharmaceuticals's revenue streams in c 23 are SPINRAZA Royalties, Licensing and Other Royalties, Other Commercial, Product, Research and Development Revenue, Commercial, and Collaborative Agreement Revenue. SPINRAZA Royalties generated $240.38M in revenue, accounting 15.84% of the company's total revenue, down -17.96% year-over-year. Licensing and Other Royalties generated $33.3M in revenue, accounting 2.19% of the company's total revenue, up 7.44% year-over-year. Other Commercial generated $68.21M in revenue, accounting 4.50% of the company's total revenue Product generated $34.91M in revenue, accounting 2.30% of the company's total revenue, up 16.18% year-over-year. Research and Development Revenue generated $479.06M in revenue, accounting 31.58% of the company's total revenue, up 68.68% year-over-year. Commercial generated $308.59M in revenue, accounting 20.34% of the company's total revenue, up 1.73% year-over-year. Collaborative Agreement Revenue generated $352.66M in revenue, accounting 23.25% of the company's total revenue, up 70.18% year-over-year.

For the fiscal year ending Dec 23, the largest source of revenue of Ionis Pharmaceuticals was Research and Development Revenue. This segment made a revenue of $479.06M, representing 31.58% of the company's total revenue.